Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HERTHENA-PanTumor01 (U31402-277): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors

Next Previous
Trial Profile

HERTHENA-PanTumor01 (U31402-277): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Patritumab Deruxtecan (Primary)
  • Indications Adenocarcinoma; Carcinoma; Gastric cancer; Head and neck cancer; Malignant melanoma; Oesophageal cancer; Solid tumours; Squamous cell cancer
  • Focus Proof of concept; Therapeutic Use
  • Acronyms HERTHENA-PanTumor01
  • Sponsors Daiichi Sankyo Company

Most Recent Events

  • 17 Sep 2024 Trial design were presented at the 49th European Society for Medical Oncology Congress.
  • 04 Sep 2024 According to Daiichi Sankyos media release, Trial-in-progress poster presentations will highlight the HERTHENA-PanTumor01 phase 2 trial at Daiichi Sankyos Second ADC Platform and DXd ADC Data in Multiple Additional Cancers at ESMO
  • 29 May 2024 Trial design discussed in an abstract published at 60th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top